RRML - Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- April 2024 -
 
A comprehensive review of Prof... 24
Recomandarea comună EFLM-COLA... 13
Monocyte to high-density lipop... 9
Anti-thyroid peroxidase (TPO) ... 9
Understanding the key differen... 7
Understanding the pathogenesis... 7
Function of the S1P pathway in... 6
Predictive value of expression... 5
The importance of tumor marker... 4
Romanian Review of Laboratory ... 4

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 25(4)/2017 DOI:10.1515/rrlm-2017-0032
XML
TXT

Research article

Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Olga Hilda Orăsan, Ljubomir Petrov, Laura Urian, Angela Cozma, George Ciulei, Ioan Mihai Patiu, Remus Aurel Orăsan

Correspondence should be addressed to: Olga Hilda Orăsan

Abstract:

Introduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (ADPKD) treated or not with ESA. Methods. Forty-six hemodialysis ADPKD patients were studied for 8 months and they were divided into: group 1- 29 patients who received ESA during the study period and group 2- 17 patients with no ESA treatment. The following parameters were determined: weekly treatment time, body mass index (BMI), pre-session diastolic blood pressure (DBP), pre-session systolic blood pressure (SBP), blood volume processed (BVD), interdialytic body weight gain (IBWG), spKt/V -K/DOQI formula (Kt/V), urea distribution volume (UDV), hemoglobin (Hb), ferritin, transferrin saturation (TSAT), serum phosphate, total serum calcium, normalized protein catabolic ratio (nPCR), albumin, and intact parathormone (PTH). Results. Patients not requiring ESA were more likely to be men, had higher Hb, albumin, total serum calcium levels, IBWG, UDV, BVP, and weekly treatment time. They had lower ferritin, TSAT, SBP. There was no difference regarding DBP, BMI, serum phosphate, PTH, Kt/V, and nPCR. Conclusion. Hemodialysis ADPKD patients not treated with ESA seem to be better nourished, with a slightly better SBP control, with longer dialysis time and increased Hb (despite lower iron loading markers), compared to hemodialysis ADPKD patients treated with ESA.

Keywords: autosomal dominant polycystic kidney disease, erythropoiesis-stimulating agents, anemia, hemodialysis

Received: 23.3.2017
Accepted: 4.9.2017
Published: 6.10.2017

 
  PDF Download full text PDF
(337 KB)
     
 
How to cite
Orăsan OH, Petrov L, Urian L, Cozma A, Ciulei G, Patiu IM, et al. Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients. Rev Romana Med Lab. 2017;25(4):375-82. DOI:10.1515/rrlm-2017-0032